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1. Introduction 
Patients with gastrointestinal cancer exhibit a poorly functioning immune system that is 
characterized, in part, by decreases in T-lymphocyte proliferation (Greenstein, et al., 1991; 
Milasiene et al., 2007) and reduced CD4+:CD8+ ratios (Arista et al., 1994; Franciosi et al., 2002). 
In different pathologies (including these and other types of cancers), membrane damage in 
immune cells (and other cell types) often evolves as a consequence of alterations that are 
induced in cell-associated lipids and proteins in the affected patients (Gryzunov and 
Dobretsov, 1994, 1998; Rolinsky et al., 2007). It is now widely accepted that the dynamics 
(actual rate of occurrence - not only incidence) of these changes, along with the types of 
alterations in structure(s) of the immune system cells’ lipids/proteins themselves, play a 
critical role in the maintenance of the immune status of any given organism (Lakowicz, 2000). 
As a result of the potential importance of changes in the structural integrity of cells of the 
immune system, it is important for clinicians to receive information on the biophysical 
status of these cells via quick, reliable, reproducible methods. In this regard, fluorescent 
probes have shown to be excellent tools for use in such protocols (Lakowicz, 2000, 2006). 
The work reported here, which built upon earlier findings reported by our laboratories, 
investigated the possibility of using the fluorescent probe ABM (an amine derivative of 
benzanthrone) for the detection of structural/functional alterations in blood plasma 
albumin and among immunocompetent cells in patients with select types of pathologies, i.e,. 
cancers. Such an analysis has a great potential for use not only for helping to comprehend 
mechanisms of immunomodulation associated with the induction/progression of 
malignancies, but might also have the potential to serve as a very important prognostic 
indicator of long-term survival among patients with such pathologies.  
In the work reported here, ABM fluorescence intensity in blood plasma and following 
combination with cell suspensions from colorectal cancer patients was examined in the 
context of the host’s immunological parameters and state of cancer progression. For study 
patients with colorectal cancer were examined: 1) 1 day before and 10 days after their 
surgical treatment (Stages II-III) (Kalnina et al., 2009); 2) as disease worsened (Stages IIa, 
IIIb, IV) (Kalnina et al., 2010b); 3) advanced cancer patients, they were divided into two 
groups in accordance of its survival rate (0-6 months and > 24 months) (Kalnina et al., 2011). 
Apart from the aforementioned potential benefits from these types of studies to clinicians in 
general, this type of research is very important in Latvia itself. This is because, in the context 
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of oncological diseases seen among the Latvian population (as recently as in 2006), colorectal 
cancers rank third in incidence, only surpassed by lung cancers and urogenital tumors. 
2. ABM: Distribution and spectral characteristics in cells and blood plasma 
A new fluorescent probe, a derivative of 3-aminobenzanthrone (ABM) at the Daugavpils 
University, Daugavpils, Latvia. 
 
 
Fig. 1.Chemical Structure of probe ABM  
Synthesis and properties of probe ABM were described in (Kalnina et al., 2004, 2007, 2009, 
2010a; Kirilova et al., 2008). 
3. ABM binding with blood plasma albumin 
3.1 ABM binding with blood plasma albumin before and after surgical treatment  
In the colorectal cancer patients, the ABM emission spectra maximum (i.e., at 650 nm)—after 
combination with the patients’ blood plasma—was not altered in comparison to that seen 
with the plasma from the healthy control volunteers. In contrast, with respect to 
fluorescence intensity, before their individual surgical treatments, the average ABM 
intensity in the patients’ blood plasma was decreased compared to that seen with the 
samples from the healthy donors. Specifically, the fluorescence associated with samples 
from the colorectal cancer group (Figure 2) were decreased by 23.0%. At 10 days after their 
operations, the average ABM fluorescence intensity in the samples from the colorectal 
cancer group were decreased further by 13.9%.  
The average intensity values of the plasma samples from the cancer patients were significantly 
(P < 0.05) different from the control volunteers’ average value. Whether these observations 
tracked actual changes in the levels of plasma albumin were also investigated. The results 
(data not shown) indicate that plasma albumin concentrations (μg/μL) pre-surgery in the 
patient group (71.73 ± 1.34 ) were below those in the plasma of the health controls (83.41 ± 
1.16). This meant that the pre-surgery values for albumin only indicated levels in colorectal 
group samples that were ≈ 14% below control, while the samples’ fluorescence intensity was 
correspondingly lower than the control value by 23.0% . The plasma albumin concentrations 
after surgery seemed to be insignificantly impacted. Specifically, these value was in colorectal 
cancer patients samples 68.48 ± 1.78 (in μg/μL, mean ± SD).  
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Fig. 2. ABM fluorescence intensity in lymphocytes and in plasma from “Colorectal group” 
patients. Colorectal cancer patients only (Stage II–III) (n = 10). Group number in figure is 
used to reflect from whom/when samples were isolated [i.e., Group 1: pre-surgery; Group 
2: post-surgery; and Group 3: from healthy donors (control group; n = 14)]. Solid bar in each 
set: ABM fluorescence in lymphocytes; hatched bar in each set: ABM fluorescence in plasma. 
All intensity values are shown in AU (arbitrary units; mean ± SE). At P < 0.05, *value 
significantly different from pre-surgical value and/or #significantly different from control 
group value.  
It is of interest to note that while the post-surgery albumin values in these patients samples 
were ≈18% below control levels, their corresponding fluorescence intensity were now even 
more depressed relative to that of the controls by ≈ 34%. These results strongly suggest that 
the noted changes in ABM fluorescence post-surgery in the cancer patients were most likely 
attributable to some change in the protein(s) themselves rather than due to post-surgery 
complications (i.e., bleeding or other mechanisms affecting blood volume/composition). To 
ascertain whether these results (different ABM spectral characteristics) could be explained, 
in part, by altered structural characteristics of the plasma albumin in the cancer patients, the 
average binding constant (Ka) values were determined using the Klotz graphical method. 
These analyses revealed that the average Ka values for the pre-surgery samples from the 
colorectal patient group decreased strongly from the respective constant associated with the 
control group (i.e., 1.0 X 105 M−1, colorectal cancer group; 1.8 X 105 M−1, healthy control 
group). These values represent decrements of from 28% to 45% in the binding of ABM to 
albumin in the plasma of these patients; the reason for the decrement remains to be fully 
determined. Interestingly, even though the fluorescence intensity values decreased further 
for the patients following their surgical procedures, the average Ka values for the samples 
from the patients increased relative to corresponding preoperative values (i.e., 1.3 X 105 
M−1).  
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3.2 ABM binding with blood plasma albumin as a function of stage 
The average ABM fluorescence intensity in patient’s blood plasma was decreased compared 
to that seen with healthy donors. Specifically, the fluorescence intensity associated with 
samples from colorectal cancer patients (Table 1) was decreased by 23% (average value of 
1.44 fluorescence units for those at Stage IIA-IIIB) and 42% (average value of 1.09 units for 
those at Stage IV) relative for the healthy controls(an average value of 1.87 units). 
 
Group Stage F (PI)a 
1 IIA-IIIB #*1.44±0.12 
2 IV *1.09±0.11 
3 Controls 1.87±0.13 
aF (PI) = fluorescence intensity in blood plasma; Values shown are in mean (± SE). 
Value (p<0.05) significantly different from that of * control or # Group 2 patients. 
Table 1. Spectral characteristics of ABM in blood plasma of colorectal cancer patients 
3.3 ABM spectral characteristics in blood plasma of advanced cancer patients 
The average ABM fluorescence intensity in the patients (Group 1 and Group 2) blood 
plasma was decreased (i.e., by 37.4% and 24.1%, respectively) as compared to that seen in 
healthy donors (Table 2). In Group 2 average intensity significantly  (p<0.05) differs from 
Group 1 value and also control group value by 10.6 % and 31.7 %, respectively. Total 
albumin (TA) concentration in Group 1 and Group 2 patients was decreased (relative to 
control value) by 23.5% and 16.1%, respectively. Effective albumin (EA) concentration was 
decreased  by 40.0% and 27.7%, respectively. The lowest value EA/TA in these patients 
plasma reached 0.61 (Group 1), and 0.66 (Group 2);  (donor group 0.79-0.81).    
 
Group 
Survival rate 
F (Pl) EA TA EA/TA 
(months) 
1 0-6 1.17 ± 0.14 39.0 + 1.1 63,80 + 1.02 0,61 
2 > 24 1.42 ± 0.09 47.0 + 1.2 70,80 + 1.14 0,66 
Control  1.87 ± 0.13 65.0 + 1.3 83,4 + 1.16 0,78 
P<0.05 
between 
groups 
 1-2, 1-3, 2-3 1-2, 1-3, 2-3 1-2, 1-3, 2-3  
F (Pl) = fluorescence intensity in blood plasma;. Values shown are in mean (± SE). 
EA- "healthy" albumin equivalent in patients plasma, g/L 
TA- total albumin concentration, g/L  
EA/TA- reserve of albumin binding capacity 
Table 2. Spectral parameters and binding sites čaracteristics of ABM in blood plasma of 
advanced cancer patients 
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4. ABM binding with lymphocytes 
4.1 ABM binding with lymphocytes before and after surgical treatment  
In the colorectal cancer patients, the ABM emission spectra maximum (i.e., at 650 nm) after 
combination with the patients’ lymphocytes (as with their plasma) was not altered in 
comparison to that seen with the cells from the healthy control volunteers. Surprisingly, the 
average ABM fluorescence intensity value noted from colorectal patients group was actually 
12.0% greater than the control level (Figure 3); however, even with this increase, the value 
was not significantly different from the average control value. In contrast to what was 
observed with the plasma samples, the average ABM fluorescence intensity values noted 
with the cells from patients at 10 days after their operations were greater than the values 
seen with the control volunteers’ cells by 44%. In comparison to the pre-operative values, 
these average ABM fluorescence intensity values at 10 days after the patients’ operations 
had increased by 28.6%.  
 
COLORECTAL CANCER PATIENTS (Stage II-III) (n=10) 
 
CD16+% aCD16+ CD4+:CD8+ CD38+% 
Lymphocytes 
(%) 
b1 ‡15.95±2.18 ‡314.18±39.27 ‡1.27±0.10 ‡3.40±1.20 28.00±1.30 
2 *‡7.93±1.43 *‡144.75±22.44 *‡1.50±0.13 *‡12.70±3.40 *‡23.50±2.20 
3(Controls) 12.50±1.10 389.00±24.11 1.88±0.16 24.60±1.60 28.00±1.30 
a Values shown are in terms of absolute numbers (mean ± SE). 
b Indicates when or from whom samples were isolated: (1) before surgical treatment; (2) after surgical 
treatment; and (3) healthy donors (control group; n=14). 
* Value significantly different from pre-surgical value (P<0.05); ‡significantly different from control 
group value (P<0.05). 
Table 3. Peripheral blood lymphocyte subpopulation counts in the distinct subsets of the 
study’s cancer patients. 
4.2 ABM binding with lymphocytes as a function of stage  
In general, among the gastrointestinal cancer patients examined here, the ABM emission 
spectra maximum (i.e., at 650 nm) after combination of the probe with the patients’ 
lymphocytes was not altered in comparison to that seen with the cells from the healthy 
control volunteers (spectral data not shown). The ABM fluorescence intensity in the samples 
from colorectal patient group in Stages IIA-IIIB was not significantly different from the 
average control value (0.28 vs. 0.25 fluorescence units, respectively; Fig.3). In contrast, there 
was a significant reduction in ths parameter among the cells from the cancer patients in 
Stage IV (a decrease of 44%; (0.14 vs. 0.25 units). 
4.3 ABM spectral characteristics in lymphocytes of advanced cancer patients    
The ABM fluorescence intensity in the samples from advanced cancer patients (Group 1) 
was not different from the average value (0.25 vs. 0.25) fluorescence units, respectively: 
(Table 4). In contrast, there was a significant increase in this parameter among the cells from 
the cancer patients Group 2 as compared with Group 1 (by 80.8%) and healthy donors (by 
112%) (0.25 vs. 0.52 units).  
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Fig. 3. ABM fluorescence intensity in lymphocytes from colorectal cancer patients  
as a function of stage. 1) Stage IIA-IIIB (black fill); 20 Stage IV (clear fill); 3) healthy  
donors (control group; stripped fill). All values are shown as mean (-+SE). At p< 0.05,  
values significantly different from that of “control patients, Group 2 patients.    
5. Lymphocyte count and subpopulations 
5.1 Lymphocytes count and subpopulations before and after surgical treatment  
The absolute number of CD3+ cells and CD16+ natural killer cells; the relative percentages 
of all lymphocytes, CD16+ and CD38+ cells; as well as the CD4+:CD8+ ratio in the blood 
samples of the healthy volunteers and of the cancer patients, before and after each 
underwent their operations, were determined. The results among the patients in the 
“colorectal” group (Table 3) indicate that, before surgery, the numbers of CD16+ cells, the 
relative percentage of CD38+ cells, and the CD4+:CD8+ ratio were each significantly 
decreased (i.e., by 19.2%, 86.2%, and 32.4%, respectively) as compared to corresponding 
control subject values. Somewhat unexpectedly, relative percentages of CD16+ cells in this 
group were actually significantly greater (by 27.6%)—and the relative percentage of 
lymphocytes no different—than in the blood of the control volunteers. Within this same 
group, after surgery, the number and percentages of CD16+ cells, as well as the percentages 
of all lymphocytes, were each significantly reduced (i.e., by 53.9%, 50.3%, and 16.1%, 
respectively) relative to corresponding pre-surgery levels. Again, the relative percentage of 
CD38+ cells and the CD4+:CD8+ ratio increased (by 27.4% and 18.1%, respectively) 
compared to pre-surgical values, but again did not reach control levels (i.e., still were 48.4 
and 20.2% lower, respectively). 
5.2 Lymphocytes count and subpopulations as a function of stage  
On the other hand, there were significant changes in the relative percentages of CD4+ cells at 
almost every stage in both cancer groups (Fig. 4). Among colorectal cancer patients, the 
percentages of CD4+ cells decreased 25.5 and 38.3% from control levels as the stages 
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progressed (actual values: 28.6%, Stage IIA-IIIB; 23.7%, Stage IV; and, 38.4%, controls). 
Patients with Stage IV colorectal cancer yielded any statistically significant shift from control 
subject levels of CD8+ cells (an increase of ≈38%, i.e., shift from 19.5% to 26.9%).  
The levels of lymphocytes (both total and the CD4+ and CD8+ sub-populations) in the blood 
samples of the cancer patients and healthy volunteers were also assessed here. The results 
show that among the patients in both cancer groups, the relative percentages of 
lymphocytes were moreover not significantly altered relative to the control levels 
irrespective of disease stage (Figures 4 and 5). Of all the patients, only those in Stage IV had 
lower blood lymphocyte levels that approached or reached statistical significance. Among 
the Stage IV colorectal cancer patients, levels were decreased 18.5% (a shift from 28.0% 
[control] down to ≈22.8%); 
 
 
 
 
 
 
Fig. 4. Lymphocyte counts (as percentage %) and T-lymphocyte subpopulation  
Levels (as % of all lymphocytes present) in cancer patients as a function of stage.  
1) Stage IIA-IIIB (black fill); 2) Stage IV (clear fill); 3) healthy donors (control group;  
striped fill).   
Because shifts in CD4+:CD8+ ratios are often used as indices of altered host immune status, 
these values were also calculated from the patients’ blood samples. The results show that 
among the colorectal cancer patients (Fig 5.), the CD4+:CD8+ ratios were all significantly 
lower than those for the healthy control subjects and became significantly further lower as 
the stage worsened. Specifically, the ratios dropped to 1.27 and 0.88 (shifts of 32.4% and 
53.2%) at Stages IIA-IIIB and IV, respectively, from the 1.88 value for the controls.   
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Fig. 5. T-lymphocyte subpopulation ratios in cancer patients as a function of stage.  
1) Stage IIA- IIIB (black fill); 2) Stage IV (clear fill); 3) healthy donors (control group; striped 
fill). 
5.3 Lymphocytes count and subpopulations in advanced cancer patients 
Among the patients in both advanced cancer groups, the relative number of lymphocytes 
were significantly decreased (i.e.by 52.6% and 39.6%, respectively) as compared to 
corresponding control values. It is necessary to note that relative number of lymphocytes in 
Group 2 is significantly higher than in the Group 1 patients, but lower than the control value 
(see Table 4). In patients with advanced cancer and metastases there is reduction in both 
numbers of lymphocytes and proportions of CD4+/CD8+ T-lymphocytes which are thought 
to play an important role in cell-mediated immunity. The results indicate that in Group 1 
and Group 2 patients the ratio CD4+/CD8+ was significantly reduced (i.e. by 58.5% and 
47.9%, respectively) relative to corresponding control level. Actual values of Group 1 and 
Group 2 – 0.78, 0.98, respectively from the 1.88 control value. It is of interest to note that in 
Group 2 this parameter stay significantly higher as compared with results in Group 1, but 
did not reached control value.  
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Group 
Survival 
rate, 
months 
F(Ly), a.u. Ly (%) CD4+(%) CD8+(%) CD4+/CD8+ 
1 0-6 0,25±0,03 13,31±1,16 20,93±1,13 27,00±1,39 0,78±0,09 
2 >24 0,53±0,11 16,95±1,18 26,14±1,32 26,70±1,31 0,98±0,08 
3 
Control 
 0,25±0,03 28,00±1,30 38,40±2,10 19,50±1,20 1,88±0,16 
p<0.05, 
between 
groups 
 1-2;2-3 1-2;1-3;2-3 1-2;1-3;2-3 1-3;2-3 1-2;1-3;2-3 
F(Ly) - fluorescence intensity in lymphocytes 
Values shown are in mean (±SE) 
Table 4. ABM fluorescence intensity in lymphocytes. Peripheral blood lymphocytes 
subpopulation counts in advanced cancer patients 
6. Examination of relationship between ABM fluorescence and blood 
lymphocyte profiles 
Pre-operation, in the colorectal patient group, the ABM fluorescence intensity was found to 
correlate with the relative number of CD38+ cells (r = +0.956). After the operations, both the 
CD4+:CD8+ ratio and relative number of CD38+ cells in patients blood was observed to be 
increased.  
In colorectal cancer group, the ABM fluorescence intensity in blood plasma and the 
lymphocytes was found to correlate with CD4+:CD8+ ratios (in all stages of cancer) and the 
percentage (%) of lymphocytes/ subtypes in their blood. The degree of any relationship 
between cancer progression/staging, lymphocyte levels, and fluorescence among the 
lymphocytes was less obvious. Specifically, in terms of disease progression, cell levels and 
fluorescence intensity weakly tracked together (i.e., r = +0.512) for the colorectal patients. . 
With respect to associations between the plasma albumin fluorescence measurements and 
each of the individual lymphocyte-associated endpoints measured (except for cell 
fluorescence itself), many of the same patterns as noted above were evident. Once again, in 
terms of disease progression, although cell levels and albumin fluorescence intensity weakly 
tracked together (i.e., r = +0.513) among the colorectal patients.  
In both groups of advanced cancer the ABM fluorescence intensity in blood plasma and 
lymphocytes was found to correlate to with CD4+/CD8+ ratios. In advanced cancer groups 
(in contrast to other groups) there is direct (not inverse) correlation between lymphocytes 
count and ABM fluorescence intensity. There seemed to be a good relationship between 
total lymphocyte (and subpopulation) levels and ABM fluorescence in both groups of 
patients. There is also good associations between the plasma albumin fluorescence 
measurements and each of the individual lymphocyte/albumin associated endpoints 
measured “effective” and total albumin concentration, reserve of albumin binding 
capacity.  
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7. Discussion 
The novel fluorescent probe ABM (an amino derivative of benzanthrone) localizes deep 
within the phospholipids bilayer of lymphocytes membrane. Thus, in studies with 
lymphocytes, it can be concluded that changes in the spectral parameters of ABM (i.e., shifts 
in magnitude of fluorescence or actual wavelength associated with normal maximal 
fluorescence [i.e., Fmax]) could reflect modifications in one/ more interdependent (i.e., 
inter-related) properties of the cells. These could include the lymphocytes’ (1) outer 
membrane physicochemical state, (2) membrane microviscosity, 
(3) proliferative activity, (4) lipid metabolism, and/or (5) phenotypical profile. As seen in 
the studies mentioned here, while the noted changes in the studied parameters (i.e., 
fluorescence behavior) could be useful in reflecting alterations in lymphocytes of the cancer 
patients in each subgroup (at both pre- and post-surgical stages), they may also ultimately 
be of use as potential indicators of alteration in cellular immunity in these individuals. 
Follow-up studies are underway to see whether this concept can be validated. We also 
sought to ascertain whether shifts in ABM binding with plasma albumin could potentially 
be utilized as a part of an overall preliminary immunodiagnostic screening test in cancer 
patients. The choice to examine albumin, among the myriad of constituents in plasma, is 
that this protein is practically the single source of ABM binding and subsequent 
fluorescence in plasma (Gryzunov and Dobretsov, 1994, 1998). Our earlier studies showed 
that within plasma, albumin is nearly alone in binding with ABM with a very high level of 
selectivity (Kalnina et al., 1996, 2004, 2007). The distribution of ABM fluorescence (intensity) 
within fractions of human plasma was seen to be albumin >>> globulins >> non-specific 
binding by other components (i.e., 90%, ≈ 5%, < 1%, respectively). These widely disparate 
binding results were confirmed in studies wherein exogenous globulin was added to plasma 
samples and there was no shift in fluorescence intensity or Fmax. Clearly, only significant 
shifts in albumin levels or alterations/ conformational changes in albumin itself seemed to 
have a major impact on these ABM fluorescence endpoints. In the present study, the 
differences in total albumin concentrations, pre- and post-surgery, among the cancer 
patients in each group did not seem to correlate well with the relative changes in ABM 
fluorescence (relative to values in control subjects’ plasma). This apparent “extra 
diminution” in fluorescence strongly suggested that there was either a novel competition for 
probe by other substances in the patients’ plasma or that the albumin in these patients had 
undergone modification(s) that affected its ability to bind ABM. The fact there were 
substantive changes in binding constant (Ka) values lends support to the latter viewpoint. 
However, this finding in and of itself does not outright preclude the possibility of the former 
event having occurred as well.These shifts in ABM binding constants in the plasma samples 
from the cancer patients, as noted earlier, could be due to a generic decreased binding 
by/conformational changes in their albumin molecules. Structural or functional alterations 
of albumin could be manifest as “shifts” away from normal “main” binding sites with high 
affinity for the probe to other binding sites with far lower affinities and specificities. Such 
shifts would be in agreement with the observations of Togashi and Ryder (2006) that 
albumin molecules are known to contain different binding sites (i.e., classes) for various 
probes. As Petitpas et al. (2001b, 2003) noted, albumin normally carries a variety of 
endogenous ligands like nonesterified fatty acids, bilirubin, and thyroxine; however, this 
protein can also bind an impressive array of drug molecules, including warfarin, ibuprofen, 
and indomethacin, as well as their metabolites (Petitpas et al., 2001a). It seems very likely 
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that patients in the groups in the present study had ingested painkillers (both prescribed 
and retail) during the course of their disease; thus, a presence of these drugs/ metabolites on 
their albumin could have contributed to the noted shifts in ABM fluorescence /Ka values. 
Our future studies will endeavor to recruit non-cancer patients with a “similar” history of 
painkiller intake in order to ascertain whether this was a main reason underlying our 
observations (regarding the albumin outcomes) or if there is something more inherently 
unique to the patient’s cancer-bearing status that influenced the measured endpoints. This 
second standpoint is not without foundation. In oncopathology, the blood plasma content of 
two important unsaturated fatty acids (i.e., oleic acid and arachidonic acid) is increased, and 
these natural constituents also increasingly occupy binding sites on albumin (Gryzunov and 
Dobretsov, 1994, 1998). Both are observed to occupy binding sites distributed across the 
protein that happen to also be bound by medium or long-chain saturated fatty acids. The 
resulting restrictions imparted on the binding configurations of the protein would then 
account for shifts in the binding affinities at the primary sites between polyunsaturated fatty 
acids and their saturated or mono-unsaturated counterparts (Petitpas et al., 2001). It remains 
to be determined whether these alterations in fatty acid composition/binding also result in 
conformational changes in the albumin that impact upon ABM binding to its major (high 
selectivity) binding sites. As noted earlier, changes in fluorescence parameters of the cancer 
patients’ lymphocytes could be reflective of changes in one/more inherent characteristics of 
their cells. In these studies, at least two, that is, proliferative activity and phenotypical 
character, could readily, albeit indirectly, be evaluated by examining changes in lymphocyte 
populations (i.e., their numbers) themselves. While the flow cytometry studies did indicate 
 significant changes in lymphocyte (and subpopulation) levels among the cancer patients, 
unfortunately, the studies failed to yield overall lymphocyte (or subtype) population 
patterns that paralleled the concurrent changes in ABM fluorescence (i.e., Table 1 vs. Figure 
2, example of this “lack of comparativeness”). Among all the subpopulation endpoints 
reported, only those of “CD38+%” and the “CD4+:CD8+ ratios” approached reflecting 
trends seen with the patients’ fluorescence measurements. Specifically, the pre-surgery 
levels of each of these cytometric values were “maximally” reduced relative to the control 
subjects’ values; post-surgery, these two values were increased, but in contrast to the 
fluorescence levels, these values did not reattain (or surpass) counterpart control levels. In 
light of the cancer patients’ post-surgical (1) persistent lower numbers of lymphocytes (both 
total and within subclasses) and (2) fluorescence values that were uniformly significantly 
greater than in control subjects’ cells, we surmise some factor(s) about these patients’ 
lymphocytes (i.e., some undefined phenotypical characteristics) can cause amplification of 
the ABM fluorescent response. The fact that this “disconnect” between these two parameters 
is most predominant during the post-operative period strongly suggests that these as yet-
undefined modifying factors in the cancer patients might be related to their general immune 
response to the surgical procedure. Our future studies will need to recruit non-cancer 
patients with a “similar” history of surgical intervention/protocols (such as among patients 
suffering enterocolitis, undergoing local biopsies for non-cancer disorders, etc.) to ascertain 
whether the surgical procedure itself was a main reason for our observations (regarding the 
“disconnect”) or whether, as with the albumin findings, there is something more inherently 
unique to a cancer-bearing status that influenced the measured endpoints. As expected, the 
CD4+:CD8+ ratios were seen to be increased in the cancer patients after they had undergone 
their respective operation. This would be expected as it is well accepted that CD4+ helper 
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cells stimulate and CD8+ (suppressor and cytotoxic) cells inhibit the immune response 
during the healing process. While that explanation for any potential changes in the 
phenotypic characteristics of these patients’ lymphocytes is somewhat straightforward, 
what is less clear is the basis for the post-surgical increase in CD38+% values and why, to 
begin with, they are lower than in the control groups. This is because, most often, increased 
levels of CD38+ cells are associated with patients suffering with lymphocytic leukemias 
than with the solid tumors (such as those associated with gastrointestinal cancers (Kalnina 
et al., 2009). In general, CD38 is expressed primarily on B-lymphocytes and T-lymphocytes, 
as well as stem/germ cells,  the CD38 ligand is an ADP-ribosyl cyclase enzyme that 
regulates the activation and growth of these lymphoid (as well as myeloid) cells . The data 
in the current study clearly show no evidence of any B-lymphocyte-based leukemia (Kalnina 
 et al., 2009) (i.e., CD16+ cell levels were lower in patients’ pre- and post-surgery blood 
samples than in controls) among the cancer patients. Thus, we conclude that the increase in 
CD38+ cell levels is more probably due to an increased presence of CD38+ T-lymphocytes. 
We conclude from our findings that the increase in CD38+ cell levels post-surgery was not 
likely due to absolute increases in T-lymphocytes, but in their activities. Such an outcome 
would be in keeping with the changes in the fluorescence values for these lymphocytes. For 
this premise to be valid, apart from showing that there are increases in relative levels of 
CD38-bearing T-lymphocytes due to activation during the post-surgery healing process, 
there still needs to be an explanation as to why these cells’ levels were initially lower in the 
patients than in the controls. One potential explanation is in the biology of the tumors 
themselves, that is, they are solid tumors of the gastrointestinal system that impact on a 
wide variety of local cell types, including the endothelium. This particular cell type in the 
gut is of interest here in that there appears to be a critical relationship among endothelial 
cells, CD38 expression, and activation of T-lymphocytes (i.e., CD4+CD45RA+ cells. It is 
plausible that normal interactions between T-lymphocytes and endothelium are likely 
“interrupted” simply as a result of changes in accessibility (secondary to alterations in gut 
architecture as tumor grew). A lack of lymphocyte– endothelium interactions could help 
explain why there was a diminution in CD38+ cell levels before surgery; during the post-
surgery recovery, angiogenic processes (i.e., during microvasculature repair/reformation at 
wound site) would allow for an increase in these particular cell–cell interactions—in 
particular, with a population of endothelial cells in very active states during the reparative 
processes. Future histopathology studies using biopsied samples from the gastrointestinal 
tracts of patients with cancers and those that underwent biopsies for non-cancer-based 
reasons (see earlier comments) should be useful in allowing us to verify the degree of these 
hypothesized cell–cell interactions. Apart from potential changes in lymphocyte–
endothelium interactions as contributing factors for the reductions (vs. controls) in CD38+ 
cell levels—and their “recoveries” after surgical removal of the tumor—in the cancer 
patients, there are other possible reasons for these two observations. Among these, 
specifically, is the fact that patients with colorectal/gastrointestinal cancers (especially those 
at more advanced stages) tend to have significant levels of circulating interleukin (IL)-4 . 
This is critical in that it has been shown, at least with B-lymphocytes, that exposure of these 
cells to IL-4 reduced the amount of CD38 antigen on and in these cells; no evidence was 
obtained for accelerated breakdown, shedding, or internalization of CD38 molecules, or for 
the accumulation of CD38 molecules in the cell interior, due to IL-4 (Kalnina et al., 2009). In 
our ongoing studies, we will analyze patients’ blood samples for IL-4 both pre- and post-
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surgery to see whether its levels reflect the observed changes in the CD38+ lymphocytes and 
their fluorescence responses (indicative of phenotypic changes likely related to activation) in 
the presence of ABM. The results of the ABM studies presented here show that, as might be 
expected, the presence of solid tumors and surgical interventions can affect the functional 
activity of lymphocytes. These results are in agreement with previously- performed 
investigations to characterize the outer cell membrane of lymphocytes of cancer patients, 
patients with autoimmune disease (i.e., rheumatoid arthritis), and workers who had been 
contaminated during the clean up at Chernobyl (Kalnina et al., 2004, 2010a, Zvagule, 2010). 
Likewise, the observed changes in the ABM spectral parameters in blood plasma are 
probably coupled with alterations in cellular mechanisms of immune regulation in the 
patients here. Ongoing studies are seeking to answer this very question. 
The studies here showed that spectral characteristics (fluorescence intensity) differed among 
the various patient sub-groups. These findings suggest likely physical (structural) and 
functional alterations in the patients’ cells were a function of cancer stage. It is known that 
ABM fluorescence intensity can change in accordance with environment polarity and, 
consequently, in relation to plasma membrane microviscosity (that in turn correlates with 
cell lipid metabolism). There are various pathological states (i.e., cancer) in which the lipid 
composition and specific fatty acid content in lymphocyte membranes and blood plasma are 
disturbed (Kalofoutis et al., 1996). For example, colorectal cancer patients have abnormal 
plasma and erythrocyte fatty acid levels, as well as of their polyunsaturated metabolites 
(Robinson et al., 2001). Ultimately, in lymphocytes, because membrane physicochemical 
status and cell lipid metabolism play pivotal roles in signal transduction pathway(s) 
activities important in maintaining cell function (Kim et al., 1999), it would not be 
unexpected that disturbances in these parameters could result in altered 
immunocompetence in hosts with these affected cells. Fluorescence intensity of ABM in 
lymphocytes suspension tended to decrease with progression of cancer. Shifts in magnitude 
of ABM fluorescence could reflect modifications in one/more interdependent properties of 
cells (Kalnina et al., 2007). As seen in the studies mentioned here, at least two parameters are 
responsible for this phenomenon. In this studies, at least two, that is proliferative activity 
and phenotypical character could readily, albeit indirectly, be evaluated by examining 
changes in lymphocytes populations (ie., their numbers) themselves. While the flow 
cytometry studirs did indicate significant changes in lymphocytes (and sunpopulations) 
levels among the cancer patients, unfortunately, the studies failed to yield overall 
lymphocyte (or subtipe) population patterns that paralleled the concurrent changes in ABM 
fluorescence example of this “lack of comparativeness”). The studie of Milasiene (Milasiene 
et al., 2007) also suggest that immunosuppression covers many aspects of the complex 
immune system, and therefore, we have many unexpected findings.   
The studies here also revealed significant changes in ABM fluorescence associated with the 
plasma (re: albumin) of the cancer patients. The choise to examine albumin, among the 
myriad of constituents in plasma, is that this protein is practically the single source of ABM 
binding and subsequent fluorescence in plasma. We know form earlier studies that plasma 
albumin binds ABM with a very high selectivity (Kalnina et al., 1996, 2004, 2007, 2009, 2010b, 
Zvagule et al., 2010) and that only very significant shifts in plasma albumin levels or 
structural changes in albumin itself seemed to impact on ABM fluorescence. In the previous 
study (Kalnina et al., 2009) the differences in total albumin concentrations in patients groups 
did not seem to correlate well with the relative changes in ABM fluorescence (relative to 
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values of control subjects plasma). The fluorescent method reveal the “effective” 
concentration of albumin (equivalent of “healthy'' albumin in blood plasma). The total 
concentration of albumin is conservative.  In general, serious alterations in plasma albumin 
levels are often reflective of poor outcomes in cancer patients (Seve et al., 2007). As noted 
above, the changes in patient plasma albumin levels (≈14-18% below control) were far less 
than the recorded shifts in ABM intensities and it seemed these measures were “picking up” 
changes beyond those that could solely be attributed to a change in total albumin status. The 
additional ‘binding shifts’ seen with the cancer patients’ plasma samples could be due, in 
part, to decreased binding by/conformational changes in their albumin. There are several 
ways in which tumor-and/or treatment-associated agents can bind to albumin and cause 
allosteric modifications that lead to structure and function changes: (1) tumor cells release a 
variety of bioactive proteins/peptide fragments - sequestration by carrier proteins (like 
albumin) protect these materials from clearance (and amplify their circulating levels; 
Kazmierczak et al., 2006); (2) plasma content of select key unsaturated fatty acids (i.e., oleic 
and arachidonic acids) is increased - these then increasingly occupy binding sites on 
albumin (Gryzunov and Dobretsov, 1994, 1998; Petitpas et al., 2001b); and, (3) an array of 
drugs, e.g., ibuprofen, indomethacin, etc. (and their metabolites) commonly ingested by 
cancer patients readily bind with albumin (Petitpas et al., 2001a, 2003). As was the case with 
lymphocytes, the shifts in cancer patient plasma ABM fluorescence intensity were related to 
disease stage. While moderate alterations in albumin-ABM signals were already noted at 
early (Stages II) phases of cancer, the effects were amplified as cancer evolved to Stages III-
IV. It is likely that as cancer progressed, the levels of pathological/pharmacological 
metabolites in the patient’s blood increased and their albumin could not ultimately bind 
them all. One consequent structural/functional alteration induced in the albumin could be a 
shift in ABM binding away from normal primary high affinity sites to others with lower 
affinities/specificities. Such shifts would be in agreement with the observations of Togashi 
and Ryder (2006) and Rolinski et al. (2007) who noted that albumin molecules contained 
different binding sites (i.e., classes) that differed in affinity, quantum yield, and degrees of 
polarization (i.e., higher mobility of bound probe and increased accessibility by water) for 
ABM and various other probes. The results of the current investigation also seemed to 
reflect what was predicted to occur based upon electron spin resonance (ESR) spectroscopy 
studies that measured structural and functional changes in serum albumin of patients with 
other cancers (Kazmierczak et al., 2006). Specifically, analyses of ESR spectra (using spin 
probes) revealed substantial differences in spectrum variables when samples from patients 
were compared with those from healthy hosts. For example, the increasing width of the 
spectral line in samples from the cancer patients indicated an alteration in albumin 
conformation that limited the movement of the spin probe at a binding site, as well as 
changes in the albumin capacity to bind spin probe, polarity of spin probe binding site, and 
probe mobility (Kazmierczak et al., 2006). While increased binding of tumor-/treatment-
associated agents (leading to the sequelea outlined above) could be a means by which 
changes in albumin-ABM fluorescence evolved here, there are other means by which the 
albumin ability to bind the probe may have been altered. While we demonstrated here there 
were changes in ABM fluorescence after inter-actions with lymphocytes (and plasma 
albumin) obtained from gastrointestinal cancer patients, another major question that needed 
addressing was whether there were actual biologic/immunologic modifications associated 
with these alterations. As noted earlier, changes in fluorescence parameters of patient 
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lymphocytes could reflect changes in one/more inherent characteristics of these cells, 
including their phenotypical character. While the flow cytometry studies identified 
significant alterations in lymphocyte (and sub-populations) levels among all the cancer 
patients, variations in total lymphocyte levels never clearly and consistently paralleled the 
corresponding changes in ABM fluorescence for the gastric cancer subjects. In contrast, there 
seemed to be a good relationship between these endpoints in the colorectal patients. For 
now, it remains unclear why there should be a divergence in these patterns based on the 
cancer type itself. 
The observed changes in ABM intensity in the lymphocytes might be useful to reflect 
current CD4+ and/or CD8+ status in the pacients. In this regard, the same (as above) disease-
related differences in the relationships were apparent between changes in ABM fluorescence 
and those in CD4+ levels in the patients. The noted shifts in CD4+ levels were expected; 
cancer- related CD4+ cell deficiency is a frequent finding in digestive system cancer patients 
(Franciosi et al, 2002). In our previous investigations, CD4+:CD8+ ratios tended to parallel 
ABM fluorescence levels (i.e., lowest among patients who manifested decreased 
fluorescence in their lymphocyte suspensions (Kalnina et al, 2007, 2009, 2010a,2010b). In 
those earlier studies, CD4+:CD8+ ratios gradually decreased as CD8+ levels increased with 
progression of cancer stage (Wang et al., 2004; Kalnina et al., 2007). In the studies here, the 
shifts seem to depend more on decreases in CD4+ levels as each disease became metastatic. 
These outcomes would be in keeping with the studies by Tancini et al. (1990) and (McMillan 
et al. (1997) that indicated that decreases in CD4+:CD8+ ratios in gastric cancer patients 
mainly depended on increases in CD8+ T-cytotoxic cells in patients with early stage disease 
whereas it was due to decreases in CD4+ T-helper cells in those with metastases (later stage 
disease). Thus, at least clearly for colorectal cancer patients, our results suggest that 
measures of ABM fluorescence intensity values for lymphocytes (and to a lesser extent, for 
plasma albumin) could potentially be used in clinical immunological screenings (instead of 
more expensive routine tests) to provide a snapshot of immune status in these cancer 
patients. Whether the utility of these measures could/would extend to human disease states 
remains to be determined.  
8. Conclusion 
Fluorescence behaviour of ABM could be useful to reflecting alterations in lymphocytes in 
each subgroup and they may ultimately be of use as potential indicators of alterations in 
cellular immunity in individuals. We also sought to ascertain whether shifts in ABM 
binding with plasma albumin could be potentially utilized as part of an overall preliminary 
immunodiagnostic screening test in cancer patients. Taken together it would appear that 
progression of cancer is associated with changes of immune function and more specifically a 
reduction in absolute number of CD4 + T-lymphocytes and either an increase or not change 
in the absolute count of CD8+ T-lynphocytes. Study suggests that higher number of absolute 
lymphocytes count and ratio CD4+: CD8+ have beneficial effect on overall survival of 
patients with advanced tumor. Overall survival depends also on quantitative parameters of 
cellular immunity of cancer patients. Thus, immune status of the immune system of  
patients with advanced tumor before treatment is important for its survival. The 
immunosuppression and metastatic spread are interconnected. The low plasma albumin 
level also were identified as bad independent marker of prognosis. Fluorescent based 
method is pertinent to pathway profiling, target validation, and clinical diagnosis, 
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prediction of therapeutic effacy, and monitoring of treatment outcomes. ABM fluorescence 
intensity values for plasma albumin and lymphocytes (as reflection of their functional 
activity) might be useful tool in the evolution of the immune status of pacients. Taken 
together, all the results showed that measures of ABM spectral characteristics could 
potentially be a useful tool to estimate the immune status of gastrointestinal patients.  
Compared to many commonly used diagnostic protocols, this fluorescence based method is 
less expensive and not very time consumming, technically simple and 100 times more 
sensitive than standard absorbance based methods.  
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